ADVERTISEMENT
Covid-19 | Serum Institute of India seeks indemnity protection: ReportThis comes a day after reports that Pfizer and Moderna were also close to an indemnity deal
DH Web Desk
Last Updated IST
dar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India. Credit: Reuters File Photo
dar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India. Credit: Reuters File Photo

The Serum Institute of India (SII), which manufactures AstraZeneca and Oxford University's Covid-19 vaccine — Covishield, has sought indemnity protection against liabilities, news agency ANI reported citing sources familiar with the matter.

ANI on Wednesday reported that Pfizer and Moderna were a step closer to indemnity deals with the government of India.

The pharma giants had sought from the government indemnity from costs relating to severe vaccine side-effects. India's apex drug regulator has also waived the requirement of testing every batch of foreign-made Covid-19 vaccines and conducting bridging trials for vaccines approved by the WHO.

ADVERTISEMENT


More details awaited.

Deccan Herald is on WhatsApp Channels | Join now for Breaking News & Editor's Picks